

The Economic Burden of Heart Diseases in Colombia

Bryce Stevens¹, Lynne Pezzullo^{1*}, Lara Verdian¹, Josh Tomlinson¹, Sasha Zegenhagen¹

¹Health Economics and Social Policy, Deloitte Access Economics, Australia.

Corresponding author: lpezzullo@deloitte.com.au

Poster code: PM021

Abstract

Heart disease (HD) is currently the leading cause of death in the Latin American region and expected to remain so for the next few decades. HD imposes health care system and other costs to society through morbidity, premature mortality, carer costs and loss of productivity. The economic burden of heart disease in the Latin American region has not been previously quantified.

Objective: The study aim was to assess the economic burden of heart failure (HF), myocardial infarction (MI), atrial fibrillation (AF), and hypertension (HTN) in Colombia and the cost effectiveness of telemedicine (TM) and structured telephone support (STS) for the treatment of HF.

Methods: The cost of four heart conditions in Colombia was estimated using a prevalence approach for HF, AF and HTN, and an incidence approach for MI. This was done by estimating the number of people with HD in a base period (2015) and the costs associated with the condition in that period. The cost estimates included health system expenditures as well as other financial costs including productivity losses (absenteeism, lower workforce participation, premature mortality) and informal care costs. We also estimated transfer costs in order to better understand how costs were borne by government, individuals and society. Estimates were also made of the value of the loss of healthy life, measured in disability adjusted life years (DALYs) using global burden of disease disability weights. To estimate the number of cases of HD in the population, by age and gender, epidemiological data on prevalence or incidence rates were applied to population data. Data inputs were informed by a targeted literature review that provided Colombia specific disease estimates and a data scan and amalgamation of Organisation for Economic Co-operation and Development, World Health Organization and regional estimates. Estimates were triangulated using semi-structured interviews with clinicians, insurers and health administrators.

Results: Accounting for co-morbidities, these HDs were found to affect approximately 5.6 million people in 2015 in Colombia (17.4% of the adult population). This leads to significant wellbeing loss, estimated at 563,659 DALYs, and economic burden, estimated at totalling 6.4 trillion pesos in 2015. Assuming a willingness to pay threshold of 15,453,843 – 46,361,529 pesos per quality adjusted life year, which equates approximately to 1 to 3 times the gross domestic product per capita in Colombia, the cost effectiveness analysis suggests that TM and STS may both be cost effective treatment options for the management of patients with HF, with TM being more cost effective than STS relative to standard care.

Conclusion: HD imposes a significant burden to the health system and society. Prevention and appropriate management of HD would result in significant benefits both in improved wellbeing and economic savings. TM and STS are cost effective mechanisms for achieving improvements in the management of heart failure.

Introduction

- Heart conditions impose physical, social, financial, and health related quality of life limitations on individuals affected. These conditions result in an economic burden and impact on society due to expenditures on health care treatment, productivity losses from employment impacts, costs of providing formal and informal care, and lost wellbeing^{1,2}
- Common risk factors for heart disease are: tobacco intake; high cholesterol; obesity; high blood pressure; diabetes; alcohol intake; dietary factors; physical inactivity and depression.³⁻⁶

Objective

- The economic burden of heart disease in the Latin American region has not been previously quantified. This study assessed the economic burden of the four main heart conditions: HTN; HF; MI; and AF in Colombia. In addition, the cost-effectiveness of TM and STS for the management of HF was assessed.

Methods

Burden of heart diseases

- The burden of heart disease in Colombia, which is a function of the number of people with the disease and associated costs in a base period (2015), was estimated using standard methodology which applies a prevalence approach for HF, AF and HTN, and an incidence approach for MI.

Figure 1.1 High level methodology



Cost-effectiveness of interventions

- The network meta-analysis and economic evaluation of home TM and STS programs after discharge in patients with HF, conducted by the National Institute for Health Research in 2013⁷ was used as the basis for a cost effectiveness analysis from the perspective of the Federación de Aseguradores Colombianos.

Data sources

- The analysis was informed by a targeted literature review, data scan and modelling, with inputs and methods validated through a consultation process with stakeholders from the Ministerio de Salud y Protección Social, Instituto de Evaluación Tecnológica en Salud and Cuenta de Alto Costo.

References

- Salomon J, et al. *The Lancet*. 2012; 380(9859), 2129–2143.
- Yusuf S, et al. *Circulation*. 2001; 104(22), 2746–2753.
- Lawes C, et al. *Comparative quantification of health risks: Global and regional burden of disease attributable to selected major risk factors*. 2004; 2-10, 39-881.
- Grigorakis D, et al. *Food Reviews International*. 2011; 27(3), 274–299.
- Bazzano LA. *WHO Library*. 2005.
- Bazzano L, et al. *Current Atherosclerosis Reports*. 2003; 5(6), 492–499.
- Pandor A, et al. *Health Technology Assessment*. 2013; (32).



Results

Prevalence of four heart conditions

- HTN has the highest prevalence of the four conditions, followed by HF
- There are a total of 6.2 million conditions; 5.6 million of these conditions account for comorbidities
- Health system costs were borne by government, private insurers and individuals, while productivity losses were borne by individuals, governments (in the form of taxation revenue forgone), and family/friends (who reduced work to provide care, in many cases).

Table 1: Prevalence of four heart conditions, Colombia 2015

Condition	Number of people	Percentage of the adult population*
HF	647,853	2.0
MI	77,849	0.2
AF	256,664	0.8
HTN	5,185,901	16.0
Total conditions	6,168,267	19.0
Total persons with any condition (i.e. accounting for comorbidities)	5,632,423	17.4

Source: Deloitte Access Economics analysis. *Percentage reflects the evidence from studies among populations aged 20 years and over.

Financial costs on society

- MI imposes the greatest financial cost (3.4 trillion pesos/1.3 billion USD), followed by HF (1.7 trillion pesos/628 million USD), HTN (764.2 billion pesos/285 million USD) and, finally, AF (578.8 billion pesos/216 million USD).

Table 2: Financial cost of heart conditions in Colombia, 2015 (millions of pesos)

Category	HF	MI	AF	HTN	Total (unadjusted)	Total (adjusted for comorbidities)^
Health system costs	735,368	2,238,407	550,474	317,621	3,841,869	3,842,701
	44%	65%	95%	42%	59%	60%
Productivity losses	943,668	1,204,905	28,345	446,577	2,623,495	2,588,839
	56%	35%	5%	58%	41%	40%
Income forgone by individuals*	461,803	995,039	22,716	263,136	1,742,694	1,718,263
	28%	29%	4%	34%	27%	27%
Income forgone by businesses*	26,000	30,665	2,283	144,691	203,639	197,639
	2%	1%	0.4%	19%	3%	3%
Opportunity cost of informal care by family/friends	338,073	28,475	-	-	366,547	366,002
	20%	1%	-	-	6%	6%
Tax revenue forgone by government**	117,792	150,726	3,345	38,750	310,614	306,936
	7%	4%	1%	5%	5%	5%
Total cost	1,679,036	3,443,312	578,819	764,198	6,465,364	6,431,540

*Comorbidities totals do not sum to the total of the individual conditions as one person can have more than one condition and the interaction between conditions causes the total estimate of the four conditions together to vary

Wellbeing loss of selected heart conditions

- The heart conditions included impose a substantial wellbeing loss of 563,659 DALYs, after adjusting for comorbidities.

Table 3: Loss of wellbeing of selected heart conditions in Colombia, 2015

Condition	YLDs	YLLs	DALYs
HF	67,068 (23%)	31,169 (11%)	98,236 (17%)
MI	500 (0.2%)	256,690 (87%)	257,191 (44%)
AF	57,421 (20%)	7,805 (3%)	65,225 (11%)
HTN	160,763 (56%)	-	160,763 (28%)
Total (unadjusted)	285,751	295,663	581,415
Total (adjusted for comorbidities)^	278,728	284,931	563,659

*Comorbidities totals do not sum to the total of the individual conditions as one person can have more than one condition and the interaction between conditions causes the total estimate of the four conditions together to vary

Impact of heart failure and cost effectiveness of interventions

- 647,853 people in Colombia had HF and the average age of an individual with HF was 61
- HF had the second largest total financial cost and cost per case of the four conditions
- HF health system costs were 735.4 billion pesos (275 million USD) which is 44% of HF total costs
- HF imposed the greatest care giver burden among the four conditions studied
- Income losses for those with HF cost a further 462 billion pesos (173 million USD)
- HF productivity impacts resulted in government taxation forgone of 118 billion pesos (44 million USD)
- Assuming a willingness to pay threshold of 15,453,843 – 46,361,529 pesos per quality adjusted life year, which equates approximately to 1 to 3 times the gross domestic product per capita in Colombia, the cost effectiveness analysis suggests that TM and STS may both be cost effective treatment options for the management of patients with HF.

Conclusion

- Heart conditions impose substantial loss of wellbeing and financial costs in Colombia and should be a public health priority
- Myocardial infarction imposed the greatest financial cost, followed by heart failure, hypertension and atrial fibrillation
- Prevention or better management of heart conditions would result in significant benefits both in improved wellbeing and economic savings
- Telemedicine and structured telephone support are cost effective mechanisms for achieving improvements in the management of heart failure.

Acknowledgements

The study was supported by the Novartis Group.